A Phase 1 interventional study of Abemaciclib and Fulvestrant in Advanced Cancer, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine a safe dose of Abemaciclib to be given to participants with advanced cancer and to determine any side effects that may be associated with Abemaciclib in this population. Efficacy measures will be used to assess the activity of Abemaciclib in this population.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Dose Expansion (Parts B, C, D, E, F and G): The participant must have histological or cytological evidence of one of the following cancers:
As defined by the (RECIST 1.1) or the Revised Response Criteria for Malignant Lymphoma
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received oral Abemaciclib administered on Days 1 through 28 of a 28-day cycle except in Cycle 1, where the study drug was administered as appropriate on Day -3 and then on Days 1 to 27. The treatment was continued until a discontinuation criterion was met or under Sponsor's discretion. Participants belonging to different Parts received the study drug as specified below: Part A: 50 mg/100 mg/150 mg/225 mg every 24 hours (Q24H) or 75mg/100 mg/150 mg/200 mg/275 mg every 12 hours (Q12H). Parts B, C, D, and E: 150 mg/200 mg Q12H. Part F: 150 mg Q12H. Part G: 200 mg Q12H along with 500 mg Fulvestrant administered intramuscularly.
Drug: Abemaciclib · Drug: Fulvestrant
Administered orally.
Also known as: LY2835219
Fulvestrant is administered intramuscularly into the buttocks in Part G only.
Number of Participants With Clinically Significant Effects
The number of participants with clinically significant findings in the study were reported in this outcome measure.
Time frame: Baseline up to 233 weeks
Percentage of Participants With Tumor Response - Overall Response Rate (ORR), Disease Control Rate (DCR)
ORR is the percentage of participants who exhibit a confirmed complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. DCR is defined as the percentage of participants in the analysis population who exhibit a stable disease (SD) or confirmed CR or PR relative to baseline during the study. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions.
Time frame: Baseline through Study Completion (Up to 285 weeks)
Pharmacokinetics (PK): Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib
PK: Cmax,ss of Abemaciclib.
Time frame: Day 28 (0, 1, 2, 4, 6, 8, 10, 24 hours post-dose) of Cycle 1
PK: Area Under the Steady State Plasma Concentration-time Curve Over 24 Hours (AUC 0-24hr,ss) of Abemaciclib
PK: AUC 0-24hr,ss of Abemaciclib.
Time frame: Day 28 (0, 1, 2, 4, 6, 8, 10, 24 hours post-dose) of Cycle 1
Part A: Recommended Dose for Phase 2 Studies
The recommended dose was determined based on a review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from the study.
Time frame: Baseline through Study Completion (Up to 285 weeks)
This study has Dose Escalation (Part A) and Dose Confirmation (Parts B, C, D, E, F, and G) phases. Participants included -Part A: participants with histological and cytological evidence of cancer; Part B: Non-small cell lung cancer; Part C: Glioblastoma multiforme; Part D: Advanced and/or metastatic breast cancer; Part E: Advanced and/or metastatic melanoma; Part F: Advanced and/or metastatic colorectal cancer. Part G: Advanced and/or metastatic breast cancer but also hormone receptor positive.
| Milestone | Part A - Cohort 1: 50 Milligrams (mg) Abemaciclib - Every 24 Hours (Q24H) | Part A - Cohort 2: 100 mg Abemaciclib - Q24H | Part A - Cohort 3: 150 mg Abemaciclib - Q24H | Part A - Cohort 4: 225 mg Abemaciclib - Q24H | Part A - Cohort 5: 75 mg Abemaciclib - Every 12 Hours (Q12H) | Part A - Cohort 6: 100 mg Abemaciclib - Q12H | Part A - Cohort 7: 150 mg Abemaciclib - Q12H | Part A - Cohort 8: 200 mg Abemaciclib - Q12H | Part A - Cohort 9: 275 mg Abemaciclib - Q12H | Part B - 150 mg Abemaciclib - Q12H | Part B - 200 mg Abemaciclib - Q12H | Part C - 150 mg Abemaciclib - Q12H | Part C - 200 mg Abemaciclib - Q12H | Part D - 150 mg Abemaciclib - Q12H | Part D - 200 mg Abemaciclib - Q12H | Part E - 150 mg Abemaciclib - Q12H | Part E - 200 mg Abemaciclib - Q12H | Part F - 150 mg Abemaciclib - Q12H | Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 3 | 3 | 4 | 3 | 7 | 3 | 26 | 42 | 2 | 15 | 25 | 22 | 13 | 13 | 15 | 19 |
| Received at least one dose of study drug | 4 | 3 | 3 | 3 | 3 | 4 | 3 | 7 | 3 | 26 | 42 | 2 | 15 | 25 | 22 | 13 | 13 | 15 | 19 |
| Completed | 2 | 3 | 3 | 3 | 3 | 4 | 3 | 6 | 2 | 24 | 38 | 2 | 14 | 22 | 21 | 10 | 11 | 13 | 16 |
| Not completed | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 0 | 1 | 3 | 1 | 3 | 2 | 2 | 3 |
| Withdrew: Progressive disease | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 0 | 0 | 3 | 1 | 3 | 1 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
The number of participants with clinically significant findings in the study were reported in this outcome measure.
| Participants | Part A - Cohort 1: 50 mg Abemaciclib - Q24H | Part A - Cohort 2: 100 mg Abemaciclib - Q24H | Part A - Cohort 3: 150 mg Abemaciclib - Q24H | Part A - Cohort 4: 225 mg Abemaciclib - Q24H | Part A - Cohort 5: 75 mg Abemaciclib - Q12H | Part A - Cohort 6: 100 mg Abemaciclib - Q12H | Part A - Cohort 7: 150 mg Abemaciclib - Q12H | Part A - Cohort 8: 200 mg Abemaciclib - Q12H | Part A - Cohort 9: 275 mg Abemaciclib - Q12H | Part B - 150 mg Abemaciclib - Q12H | Part B - 200 mg Abemaciclib - Q12H | Part C - 150 mg Abemaciclib - Q12H | Part C - 200 mg Abemaciclib - Q12H | Part D - 150 mg Abemaciclib - Q12H | Part D - 200 mg Abemaciclib - Q12H | Part E - 150 mg Abemaciclib - Q12H | Part E - 200 mg Abemaciclib - Q12H | Part F - 150 mg Abemaciclib - Q12H | Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Effects | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 5 | 0 | 1 | 2 | 4 | 0 | 2 | 0 | 6 |
ORR is the percentage of participants who exhibit a confirmed complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. DCR is defined as the percentage of participants in the analysis population who exhibit a stable disease (SD) or confirmed CR or PR relative to baseline during the study. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions.
| Percentage of participants | Part B - 150 mg Abemaciclib - Q12H | Part B - 200 mg Abemaciclib - Q12H | Part C - 150 mg Abemaciclib - Q12H | Part C - 200 mg Abemaciclib - Q12H | Part D - 150 mg Abemaciclib - Q12H | Part D - 200 mg Abemaciclib - Q12H | Part E - 150 mg Abemaciclib - Q12H | Part E - 200 mg Abemaciclib - Q12H | Part F - 150 mg Abemaciclib - Q12H | Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant (Measurable Disease) | Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant (Non-measurable Disease) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ORR | 3.8 (0.1 to 19.6) | 2.4 (0.1 to 12.6) | 0 (NA to NA) | 0 (NA to NA) | 32.0 (14.9 to 53.5) | 18.2 (5.2 to 40.3) | 0 (NA to NA) | 7.7 (0.2 to 36.0) | 0 (NA to NA) | 45.5 (16.7 to 76.6) | 0 (NA to NA) |
| DCR | 42.3 (23.4 to 63.1) | 52.4 (36.4 to 68.0) | 0 (NA to NA) | 20 (4.3 to 48.1) | 68.0 (46.5 to 85.1) | 72.7 (49.8 to 89.3) | 23.1 (5.0 to 53.8) | 30.8 (9.1 to 61.4) | 13.3 (1.7 to 40.5) | 72.7 (39.0 to 94.0) | 87.5 (47.3 to 99.7) |
PK: Cmax,ss of Abemaciclib.
| nanograms per milliliter (ng/mL) | 50 mg Abemaciclib - Q24H | 100 mg Abemaciclib - Q24H | 150 mg Abemaciclib - Q24H | 225 mg Abemaciclib - Q24H | 75 mg Abemaciclib - Q12H | 100 mg Abemaciclib - Q12H | 150 mg Abemaciclib - Q12H | 200 mg Abemaciclib - Q12H | 275 mg Abemaciclib - Q12H |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib | NA ± NA | 102 ± 198 | 189 ± 35 | 121 ± 38 | 58.7 ± 37 | 226 ± 51 | 249 ± 86 | 298 ± 72 | — |
PK: AUC 0-24hr,ss of Abemaciclib.
| nanogram hour per milliliter (ng*h/mL) | 50 mg Abemaciclib - Q24H | 100 mg Abemaciclib - Q24H | 150 mg Abemaciclib - Q24H | 225 mg Abemaciclib - Q24H | 75 mg Abemaciclib - Q12H | 100 mg Abemaciclib - Q12H | 150 mg Abemaciclib - Q12H | 200 mg Abemaciclib - Q12H | 275 mg Abemaciclib - Q12H |
|---|---|---|---|---|---|---|---|---|---|
| PK: Area Under the Steady State Plasma Concentration-time Curve Over 24 Hours (AUC 0-24hr,ss) of Abemaciclib | NA ± NA | 1840 ± 172 | NA ± NA | NA ± NA | 1300 ± 49 | 3910 ± 53 | 4280 ± 94 | 5520 ± 70 | — |
The recommended dose was determined based on a review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from the study.
| milligrams every 12 hours (mg Q12H) | Part A - Abemaciclib |
|---|---|
| Part A: Recommended Dose for Phase 2 Studies | 200 |
Collected over Baseline through End of Treatment (Up to 645 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - Cohort 1: 50 mg Abemaciclib - Q24H | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Part A - Cohort 2: 100 mg Abemaciclib - Q24H | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part A - Cohort 3: 150 mg Abemaciclib - Q24H | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part A - Cohort 4: 225 mg Abemaciclib - Q24H | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part A - Cohort 5: 75 mg Abemaciclib - Q12H | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part A - Cohort 6: 100 mg Abemaciclib - Q12H | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Part A - Cohort 7: 150 mg Abemaciclib - Q12H | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part A - Cohort 8: 200 mg Abemaciclib - Q12H | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Part A - Cohort 9: 275 mg Abemaciclib - Q12H | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Part B - 150 mg Abemaciclib - Q12H | 3/26 (11.5%) | 7/26 (26.9%) | 26/26 (100%) |
| Part B - 200 mg Abemaciclib - Q12H | 15/42 (35.7%) | 15/42 (35.7%) | 42/42 (100%) |
| Part C - 150 mg Abemaciclib - Q12H | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Part C - 200 mg Abemaciclib - Q12H | 7/15 (46.7%) | 3/15 (20%) | 15/15 (100%) |
| Part D - 150 mg Abemaciclib - Q12H | 4/25 (16%) | 5/25 (20%) | 25/25 (100%) |
| Part D - 200 mg Abemaciclib - Q12H | 0/22 (0%) | 7/22 (31.8%) | 22/22 (100%) |
| Part E - 150 mg Abemaciclib - Q12H | 1/13 (7.7%) | 5/13 (38.5%) | 13/13 (100%) |
| Part E - 200 mg Abemaciclib - Q12H | 5/13 (38.5%) | 5/13 (38.5%) | 13/13 (100%) |
| Part F - 150 mg Abemaciclib - Q12H | 0/15 (0%) | 3/15 (20%) | 15/15 (100%) |
| Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant | 2/19 (10.5%) | 4/19 (21.1%) | 19/19 (100%) |
| Event | Part A - Cohort 1: 50 mg Abemaciclib - Q24H | Part A - Cohort 2: 100 mg Abemaciclib - Q24H | Part A - Cohort 3: 150 mg Abemaciclib - Q24H | Part A - Cohort 4: 225 mg Abemaciclib - Q24H | Part A - Cohort 5: 75 mg Abemaciclib - Q12H | Part A - Cohort 6: 100 mg Abemaciclib - Q12H | Part A - Cohort 7: 150 mg Abemaciclib - Q12H | Part A - Cohort 8: 200 mg Abemaciclib - Q12H | Part A - Cohort 9: 275 mg Abemaciclib - Q12H | Part B - 150 mg Abemaciclib - Q12H | Part B - 200 mg Abemaciclib - Q12H | Part C - 150 mg Abemaciclib - Q12H | Part C - 200 mg Abemaciclib - Q12H | Part D - 150 mg Abemaciclib - Q12H | Part D - 200 mg Abemaciclib - Q12H | Part E - 150 mg Abemaciclib - Q12H | Part E - 200 mg Abemaciclib - Q12H | Part F - 150 mg Abemaciclib - Q12H | Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SeizureNervous system disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/7 | 0/3 | 0/26 | 0/42 | 1/2 | 1/15 | 0/25 | 0/22 | 0/13 | 0/13 | 0/15 | 0/19 |
| Small intestinal obstructionGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 0/3 | 1/3 | 1/4 | 0/3 | 0/7 | 0/3 | 0/26 | 0/42 | 0/2 | 0/15 | 0/25 | 0/22 | 0/13 | 0/13 | 0/15 | 0/19 |
| ChillsGeneral disorders | 0/4 | 0/3 | 1/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/7 | 0/3 | 0/26 | 0/42 | 0/2 | 0/15 | 0/25 | 0/22 | 0/13 | 0/13 | 0/15 | 0/19 |
| BronchitisInfections and infestations | 0/4 | 0/3 | 1/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/7 | 0/3 | 0/26 | 0/42 | 0/2 | 0/15 | 0/25 | 0/22 | 0/13 | 0/13 | 0/15 | 0/19 |
| Large intestine infectionInfections and infestations | 0/4 | 0/3 | 1/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/7 | 0/3 | 0/26 | 0/42 | 0/2 | 0/15 | 0/25 | 0/22 | 0/13 | 0/13 | 0/15 | 0/19 |
| Neutropenic sepsisInfections and infestations | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/7 | 1/3 | 0/26 | 0/42 | 0/2 | 0/15 | 0/25 | 0/22 | 0/13 | 0/13 | 0/15 | 0/19 |
| PneumoniaInfections and infestations | 0/4 | 0/3 | 1/3 | 0/3 | 0/3 | 0/4 | 1/3 | 0/7 | 0/3 | 2/26 | 2/42 | 0/2 | 0/15 | 0/25 | 2/22 | 0/13 | 1/13 | 0/15 | 0/19 |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 1/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/7 | 0/3 | 0/26 | 0/42 | 0/2 | 0/15 | 0/25 | 0/22 | 0/13 | 0/13 | 0/15 | 0/19 |
| Pneumatosis intestinalisGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 1/4 | 0/3 | 0/7 | 0/3 | 0/26 | 0/42 | 0/2 | 0/15 | 0/25 | 0/22 | 0/13 | 0/13 | 0/15 | 0/19 |
| Abdominal wall abscessInfections and infestations | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 1/7 | 0/3 | 0/26 | 0/42 | 0/2 | 0/15 | 0/25 | 0/22 | 0/13 | 0/13 | 0/15 | 0/19 |
| Event | Part A - Cohort 1: 50 mg Abemaciclib - Q24H | Part A - Cohort 2: 100 mg Abemaciclib - Q24H | Part A - Cohort 3: 150 mg Abemaciclib - Q24H | Part A - Cohort 4: 225 mg Abemaciclib - Q24H | Part A - Cohort 5: 75 mg Abemaciclib - Q12H | Part A - Cohort 6: 100 mg Abemaciclib - Q12H | Part A - Cohort 7: 150 mg Abemaciclib - Q12H | Part A - Cohort 8: 200 mg Abemaciclib - Q12H | Part A - Cohort 9: 275 mg Abemaciclib - Q12H | Part B - 150 mg Abemaciclib - Q12H | Part B - 200 mg Abemaciclib - Q12H | Part C - 150 mg Abemaciclib - Q12H | Part C - 200 mg Abemaciclib - Q12H | Part D - 150 mg Abemaciclib - Q12H | Part D - 200 mg Abemaciclib - Q12H | Part E - 150 mg Abemaciclib - Q12H | Part E - 200 mg Abemaciclib - Q12H | Part F - 150 mg Abemaciclib - Q12H | Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 2/4 | 3/3 | 1/3 | 3/3 | 2/3 | 2/4 | 1/3 | 2/7 | 2/3 | 15/26 | 26/42 | 1/2 | 4/15 | 7/25 | 10/22 | 5/13 | 2/13 | 6/15 | 5/19 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 1/3 | 2/3 | 1/3 | 2/3 | 4/4 | 2/3 | 7/7 | 3/3 | 16/26 | 29/42 | 1/2 | 9/15 | 21/25 | 18/22 | 9/13 | 13/13 | 10/15 | 17/19 |
| NauseaGastrointestinal disorders | 2/4 | 2/3 | 2/3 | 3/3 | 2/3 | 2/4 | 2/3 | 6/7 | 3/3 | 18/26 | 31/42 | 0/2 | 6/15 | 19/25 | 18/22 | 13/13 | 5/13 | 10/15 | 18/19 |
| FatigueGeneral disorders | 3/4 | 3/3 | 3/3 | 3/3 | 1/3 | 4/4 | 3/3 | 5/7 | 2/3 | 20/26 | 37/42 | 0/2 | 14/15 | 20/25 | 17/22 | 11/13 | 9/13 | 10/15 | 15/19 |
| ProstatitisReproductive system and breast disorders | 0/3 | 0/1 | 0/1 | 0/2 | 0/1 | 0/2 | — | 1/1 | — | 0/11 | 0/21 | 0/1 | 0/6 | 0/1 | — | 0/10 | 0/8 | 0/6 | — |
| Vulvovaginal drynessReproductive system and breast disorders | 0/1 | 0/2 | 0/2 | 1/1 | 0/2 | 0/2 | 0/3 | 0/6 | 0/3 | 0/15 | 0/21 | 0/1 | 0/9 | 0/24 | 0/22 | 0/3 | 0/5 | 0/9 | 0/19 |
| HypertensionVascular disorders | 0/4 | 2/3 | 3/3 | 3/3 | 1/3 | 2/4 | 2/3 | 4/7 | 0/3 | 15/26 | 23/42 | 1/2 | 6/15 | 8/25 | 10/22 | 4/13 | 10/13 | 6/15 | 6/19 |
| Drug hypersensitivityImmune system disorders | 0/4 | 1/3 | 0/3 | 1/3 | 0/3 | 3/4 | 0/3 | 1/7 | 1/3 | 7/26 | 6/42 | 0/2 | 3/15 | 7/25 | 10/22 | 1/13 | 1/13 | 3/15 | 9/19 |
| Peripheral sensory neuropathyNervous system disorders | 3/4 | 2/3 | 2/3 | 1/3 | 2/3 | 3/4 | 1/3 | 2/7 | 0/3 | 7/26 | 11/42 | 0/2 | 2/15 | 9/25 | 10/22 | 4/13 | 4/13 | 7/15 | 3/19 |
| AnaemiaBlood and lymphatic system disorders | 0/4 | 1/3 | 1/3 | 2/3 | 0/3 | 1/4 | 1/3 | 1/7 | 2/3 | 13/26 | 25/42 | 0/2 | 3/15 | 5/25 | 11/22 | 6/13 | 5/13 | 6/15 | 7/19 |
All participants who received at least one dose of study drug.
| Age, Categorical(Participants) | Part A - Cohort 1: 50 mg Abemaciclib - Q24H | Part A - Cohort 2: 100 mg Abemaciclib - Q24H | Part A - Cohort 3: 150 mg Abemaciclib - Q24H | Part A - Cohort 4: 225 mg Abemaciclib - Q24H | Part A - Cohort 5: 75 mg Abemaciclib - Q12H | Part A - Cohort 6: 100 mg Abemaciclib - Q12H | Part A - Cohort 7: 150 mg Abemaciclib - Q12H | Part A - Cohort 8: 200 mg Abemaciclib- Q12H | Part A - Cohort 9: 275 mg Abemaciclib - Q12H | Part B - 150 mg Abemaciclib - Q12H | Part B - 200 mg Abemaciclib - Q12H | Part C - 150 mg Abemaciclib - Q12H | Part C - 200 mg Abemaciclib - Q12H | Part D - 150 mg Abemaciclib - Q12H | Part D - 200 mg Abemaciclib - Q12H | Part E - 150 mg Abemaciclib - Q12H | Part E - 200 mg Abemaciclib - Q12H | Part F - 150 mg Abemaciclib - Q12H | Part G - 200 mg Abemaciclib (Q12H)+ Fulvestrant | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 1 | 1 | 1 | 2 | 4 | 2 | 5 | 2 | 11 | 23 | 0 | 13 | 18 | 19 | 5 | 5 | 8 | 12 | 136 |
| >=65 years | 0 | 2 | 2 | 2 | 1 | 0 | 1 | 2 | 1 | 15 | 19 | 2 | 2 | 7 | 3 | 8 | 8 | 7 | 7 | 89 |
| Sex: Female, Male(Participants) | Part A - Cohort 1: 50 mg Abemaciclib - Q24H | Part A - Cohort 2: 100 mg Abemaciclib - Q24H | Part A - Cohort 3: 150 mg Abemaciclib - Q24H | Part A - Cohort 4: 225 mg Abemaciclib - Q24H | Part A - Cohort 5: 75 mg Abemaciclib - Q12H | Part A - Cohort 6: 100 mg Abemaciclib - Q12H | Part A - Cohort 7: 150 mg Abemaciclib - Q12H | Part A - Cohort 8: 200 mg Abemaciclib- Q12H | Part A - Cohort 9: 275 mg Abemaciclib - Q12H | Part B - 150 mg Abemaciclib - Q12H | Part B - 200 mg Abemaciclib - Q12H | Part C - 150 mg Abemaciclib - Q12H | Part C - 200 mg Abemaciclib - Q12H | Part D - 150 mg Abemaciclib - Q12H | Part D - 200 mg Abemaciclib - Q12H | Part E - 150 mg Abemaciclib - Q12H | Part E - 200 mg Abemaciclib - Q12H | Part F - 150 mg Abemaciclib - Q12H | Part G - 200 mg Abemaciclib (Q12H)+ Fulvestrant | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 2 | 1 | 2 | 2 | 3 | 6 | 3 | 15 | 21 | 1 | 9 | 24 | 22 | 3 | 5 | 9 | 19 | 150 |
| Male | 3 | 1 | 1 | 2 | 1 | 2 | 0 | 1 | 0 | 11 | 21 | 1 | 6 | 1 | 0 | 10 | 8 | 6 | 0 | 75 |
| Ethnicity (NIH/OMB)(Participants) | Part A - Cohort 1: 50 mg Abemaciclib - Q24H | Part A - Cohort 2: 100 mg Abemaciclib - Q24H | Part A - Cohort 3: 150 mg Abemaciclib - Q24H | Part A - Cohort 4: 225 mg Abemaciclib - Q24H | Part A - Cohort 5: 75 mg Abemaciclib - Q12H | Part A - Cohort 6: 100 mg Abemaciclib - Q12H | Part A - Cohort 7: 150 mg Abemaciclib - Q12H | Part A - Cohort 8: 200 mg Abemaciclib- Q12H | Part A - Cohort 9: 275 mg Abemaciclib - Q12H | Part B - 150 mg Abemaciclib - Q12H | Part B - 200 mg Abemaciclib - Q12H | Part C - 150 mg Abemaciclib - Q12H | Part C - 200 mg Abemaciclib - Q12H | Part D - 150 mg Abemaciclib - Q12H | Part D - 200 mg Abemaciclib - Q12H | Part E - 150 mg Abemaciclib - Q12H | Part E - 200 mg Abemaciclib - Q12H | Part F - 150 mg Abemaciclib - Q12H | Part G - 200 mg Abemaciclib (Q12H)+ Fulvestrant | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 3 | 0 | 0 | 4 | 4 | 2 | 1 | 3 | 3 | 27 |
| Not Hispanic or Latino | 4 | 2 | 3 | 3 | 2 | 3 | 2 | 7 | 2 | 24 | 39 | 2 | 15 | 21 | 18 | 11 | 12 | 11 | 16 | 197 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Part A - Cohort 1: 50 mg Abemaciclib - Q24H | Part A - Cohort 2: 100 mg Abemaciclib - Q24H | Part A - Cohort 3: 150 mg Abemaciclib - Q24H | Part A - Cohort 4: 225 mg Abemaciclib - Q24H | Part A - Cohort 5: 75 mg Abemaciclib - Q12H | Part A - Cohort 6: 100 mg Abemaciclib - Q12H | Part A - Cohort 7: 150 mg Abemaciclib - Q12H | Part A - Cohort 8: 200 mg Abemaciclib- Q12H | Part A - Cohort 9: 275 mg Abemaciclib - Q12H | Part B - 150 mg Abemaciclib - Q12H | Part B - 200 mg Abemaciclib - Q12H | Part C - 150 mg Abemaciclib - Q12H | Part C - 200 mg Abemaciclib - Q12H | Part D - 150 mg Abemaciclib - Q12H | Part D - 200 mg Abemaciclib - Q12H | Part E - 150 mg Abemaciclib - Q12H | Part E - 200 mg Abemaciclib - Q12H | Part F - 150 mg Abemaciclib - Q12H | Part G - 200 mg Abemaciclib (Q12H)+ Fulvestrant | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 5 |
| White | 4 | 3 | 3 | 3 | 3 | 4 | 3 | 7 | 2 | 24 | 39 | 2 | 15 | 24 | 20 | 13 | 13 | 12 | 18 | 212 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A - Cohort 1: 50 mg Abemaciclib - Q24H | Part A - Cohort 2: 100 mg Abemaciclib - Q24H | Part A - Cohort 3: 150 mg Abemaciclib - Q24H | Part A - Cohort 4: 225 mg Abemaciclib - Q24H | Part A - Cohort 5: 75 mg Abemaciclib - Q12H | Part A - Cohort 6: 100 mg Abemaciclib - Q12H | Part A - Cohort 7: 150 mg Abemaciclib - Q12H | Part A - Cohort 8: 200 mg Abemaciclib- Q12H | Part A - Cohort 9: 275 mg Abemaciclib - Q12H | Part B - 150 mg Abemaciclib - Q12H | Part B - 200 mg Abemaciclib - Q12H | Part C - 150 mg Abemaciclib - Q12H | Part C - 200 mg Abemaciclib - Q12H | Part D - 150 mg Abemaciclib - Q12H | Part D - 200 mg Abemaciclib - Q12H | Part E - 150 mg Abemaciclib - Q12H | Part E - 200 mg Abemaciclib - Q12H | Part F - 150 mg Abemaciclib - Q12H | Part G - 200 mg Abemaciclib (Q12H)+ Fulvestrant | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 4 | 3 | 3 | 3 | 3 | 4 | 3 | 7 | 3 | 26 | 42 | 2 | 15 | 25 | 22 | 13 | 13 | 15 | 19 | 225 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2009 to primary completion in May 2014, 53 months.
Results were first posted in Sep 2024, 10 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib